Objectives: Many smokers use e-cigarettes and licensed nicotine replacement therapy (NRT), often in an attempt to reduce their cigarette consumption. We estimated how far changes in prevalence of e-cigarette and NRT use while smoking was accompanied by changes in cigarette consumption at the population level.
• This is the first time series study to assess the population level impact of the use of NRT and e-cigarettes for harm reduction on cigarette consumption • This study uses a large representative sample of the population in England and considers both smoking reduction and temporary abstinence • A wide range of confounders are adjusted for including population level interventions • In countries with weaker tobacco control, or stricter regulation of using products for harm reduction, different effects may be observed.
• Data are observational and so strong conclusions regarding cause and effect cannot be made
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INTRODUCTION
Randomised controlled trials have shown that use of non-tobacco nicotine containing products are efficacious for harm reduction attempts. Harm reduction is defined as any attempt to reduce the harm from smoking without an intention to quit completely, such as, the use of Nicotine Replacement Therapy (NRT) for smoking reduction or during periods of temporary abstinence [1] . Outside of the clinical setting where little behavioural support is provided, the use of NRT during attempts to cut down appears to increase smoker's propensity to quit, but does not result in significantly large reductions in cigarette consumption [2] [3] [4] . Explanations for this include the lack of behavioural support and possible poor compliance with the medical regimen [5 6 ].
In recent years, there has been an increase in the overall use of nicotine containing products for harm reduction, with a growth in e-cigarettes more than offsetting a decline in the use of licensed products [7] [8] [9] . Previous studies suggest that e-cigarettes reduce cravings more effectively than NRT [7 10 11] , have better adherence rates [7 12] , and deliver clinically significant levels of nicotine into the blood, at least for some smokers [10 11 13] . Thus, ecigarettes may be a more effective aid for smoking reduction than licensed nicotine products [14 15 ]. However, it also remains possible that e-cigarettes will not result in clinically significant reductions in cigarette intake at a population level.
The aim of this study, using data from the Smoking Toolkit Study (STS), was to assess the association between changes in prevalence of e-cigarettes and NRT with changes in mean cigarette consumption per day using a time-series approach. Time-series analysis allows us to take into account underlying trends, the effect of other tobacco control interventions, autocorrelation (whereby data collected at points closer in time tends to be more similar), and to consider possible lag effects of the independent variable on the dependent variable [16] . Where associations are found, they cannot unequivocally establish a causal association but can be indicative, as has been the case with estimating the effect of price of cigarettes on population consumption [17] , mass media expenditure on use of specialist stop smoking services [18] , and introduction of varenicline to the market on prevalence of use of smoking cessation medication [19] . Where associations are not found, or they go in a direction opposite to that expected, this can also be informative.
Specifically, this paper assesses the association between mean cigarette consumption per day with:
1. E-cigarette use among smokers 2. NRT use among smokers
In both instances, three models will be assessed separately assessing current use for any purpose, current use specifically for smoking reduction, and current use specifically for
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METHODS

Data sources
Data on explanatory variables
The STS is a monthly survey of a representative sample of the population in England aged 16+ [20] . This has been collecting data on smoking patterns among smokers and recent exsmokers since November 2006. Questions on the use of e-cigarettes among all smokers were introduced in May 2011 and as aids to a quit attempt among smokers attempting to stop in July 2009. The STS involves monthly household surveys using a random location sampling design, with initial random selection of grouped output areas (containing 300 households), stratified by ACORN (sociodemographic) characteristics (http://www.caci.co.uk/acron/acornmap.asp) and region. Interviewers then choose which houses within these areas are most likely to fulfil quotas based on the probability of being at home tailored to region and conduct face-to-face computer assisted interviews with one member per household. Participants from the STS appear to be representative of the population in England, having similar socio-demographic composition as other large national surveys, such as the Health Survey for England [20] .
Participants who reported that they smoked cigarettes (including hand-rolled) every day or that they smoked cigarettes (including hand-rolled) but not every day, were asked the following questions:
1. Which, if any, of the following are you currently using to help you cut down the amount you smoke? Answers: nicotine gum, nicotine replacement lozenges\tablets, nicotine replacement inhaler, nicotine replacement nasal spray, nicotine patch, electronic cigarette, nicotine mouth spray, other. 2. Do you regularly use any of the following in situations when you are not allowed to smoke? Answer: nicotine gum, nicotine replacement lozenges\tablets, nicotine replacement inhaler, nicotine replacement nasal spray, nicotine patch, electronic cigarette, nicotine mouth spray, other. 3. Can I check, are you using any of the following either to help you stop smoking, to help you cut down or for any other reason at all? Answer: nicotine gum, nicotine replacement lozenges\tablets, nicotine replacement inhaler, nicotine replacement nasal spray, nicotine patch, electronic cigarette, nicotine mouth spray, other.
Smokers answering electronic cigarettes to any of the three questions were categorised as current e-cigarette users, while smokers answering an NRT product were classed as current NRT users. Smokers answering electronic cigarettes and NRT to the first question were categorised as using e-cigarettes and NRT for smoking reduction respectively, while those answering electronic cigarettes and NRT to the second question were categorised as using e-cigarettes and NRT for temporary abstinence respectively. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Daily NRT and e-cigarette users were classified as those who reported that they used the product(s) at least once per day in response to the question: How many times per day on average do you use your nicotine replacement product or products? This question was introduced in July-2010. Prior to this time, prevalence of daily NRT use was assumed to be 60% of all users [6] , while e-cigarette prevalence was computed as above using prevalence during a quit attempt or 0.1%.
Data on outcome variables
Smokers taking part in the STS were also asked how many cigarettes they smoke on average per day.
Data on other co-variables
In England, tobacco mass media campaigns have been run as part of a national tobacco control programme. Spending was almost completely suspended in 2010 and then reintroduced in 2011 at a much lower level. Previous studies have shown that such cuts were associated with a decreased use of smoking cessation support [18 23 ]. Thus, advertising expenditure will be adjusted for using data obtained from Public Health England. Data on mass media expenditure was available monthly from May 2008, and yearly prior to this period, and so a monthly average was assumed. For a number of months spending was effectively zero and was imputed as 0.1 to allow the analysis to run.
A number of tobacco control policies were adjusted for. These included the move in commissioning of stop smoking services to local authorities in April 2013 [24] , introduction of a smoking ban in July 2007 [25] , licensing of NRT for harm reduction in December 2009 [26] , the publication of NICE guidance on harm reduction in June 2013 [27] , and change in the minimum age of sale of cigarettes October 2007 [28] . Price of cigarettes is correlated 0.99 with time and will thereby be taken into account by use of differencing to make the series stationary.
ANALYSIS
The analysis plan was registered on the Open Science Framework prior to data analysis (https://osf.io/6swk3/). All data were analysed in R version 3.2.4 [29] using Autoregressive Integrated Moving Average with Exogeneous Input (ARIMAX) modelling [16 30 31] . Data were weighted prior to the analyse to match the population in England (for more details see [20] ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 6 | P a g e was no theoretical reason we could identify for a bi-directional relationship between ecigarette use and cigarette consumption. It was assumed that the association was spurious and likely removed following adjustment for other covariates.
Both unadjusted and fully adjusted models are reported which regressed onto mean cigarette consumption per day 1) use of e-cigarettes among current smokers; 2) use of ecigarettes for smoking reduction; 3) use of e-cigarettes for temporary abstinence; 4) use of NRT for harm reduction; 5) use of NRT for temporary abstinence and 6) use of NRT for smoking reduction. Sensitivity analyses were conducted which constrained the analysis to only those reporting daily e-cigarette and NRT use. We followed a standard ARIMAX modelling approach [16 34] . The series were first log-transformed to stabilise the variance, and if required, first differenced and seasonally differenced. The autocorrelation and partial autocorrelation functions were then examined in order to determine the seasonal and nonseasonal moving average (MA) and autoregressive terms (AR). To identify the most appropriate transfer function for the continuous explanatory variables the sample crosscorrelation function was checked for each ARIMAX model. Coefficients can be interpreted as estimates of the percentage change in cigarette consumption for every a) percentage increase in use of e-cigarettes and NRT, b) percentage increase in mass media expenditure, and c) implementation of tobacco control policies.
Bayes factors (BF) were derived for non-significant findings using an online calculator [35] to disentangle whether there is evidence for the null hypothesis of no effect (Bayes Factor <1/3 rd ) or the data are insensitive (Bayes Factor between 1/3 rd and 3). A half-normal distribution was assumed with a percentage change in the outcomes of interest for every percentage increase in the input series of 0.009% based on the effect detectable with 80% power (see sample size). Sensitivity analyses were conducted using a much larger percentage change of 0.1. This was based on a meta-analysis assessing the efficacy of nontobacco nicotine replacement products for harm reduction, which reported that 21.8% of the experimental group had reduced consumption by more than 50% at final follow-up compared with 16.5% receiving placebo [1] . We therefore assumed that a 5% change in prevalence of NRT and e-cigarettes would be associated with a 0.5% change in overall cigarette consumption.
STROBE guidelines for the reporting of observational studies were followed throughout [36] .
Sample size
Simulation-based power analyses suggested that this study would have 80% power to detect a change in the output series of 0.009% for every 1% change in the input series, assuming 113 monthly data collection points, MA(1) autocorrelation [37] , a baseline proportion for the input series of 0.005 [9] , a baseline mean (SD) for the output series of 12.3 [38] , and a total change over time for the input series of 30% [38] .
RESULTS
Sample characteristics
Data were collected on 199,483 adults aged 16+ taking part in the STS who reported their smoking status between November 2006 and March 2016. Of these, 43,608 (20.8%: 95%CI 20.6 to 21.0) were current smokers. Fifty-two percent (95%CI 52.0 to 53.0) of smokers were male and 60.4% (95%CI 60.0 to 60.1%) were in routine or manual positions or were unemployed. The average age of smokers in this study was 42.1 years (95%CI 42.0 to 42.1) Figure 1 shows that current use of e-cigarettes among smokers for harm reduction increased from negligible use in the last quarter of 2006 to 17.1% at the end of the study (mean 7.8%, Figure 2 shows that there was also a decline in the use of NRT for harm reduction from 12.2% to 6.0% (mean 14.4%, SD 4.36). Cigarette consumption also declined over the study period from 13.6 to 12.3 (mean 12.4, SD 0.92). Supplementary Figures 1 and 2 show the changes in e-cigarette and NRT use for smoking reduction and temporary abstinence, respectively. Tables 2, 3 and 4 show the results of the ARIMAX models assessing the association between cigarette consumption per day with 1) e-cigarette use among current smokers and NRT use for harm reduction; 2) e-cigarette and NRT use for smoking reduction and 3) ecigarette and NRT use for temporary abstinence. The findings were inconclusive as to whether or not an association was present between use of e-cigarettes and NRT for any purpose and cigarette consumption.
Main analysis
Bayes Factors were between 1/3 rd and 3 when assuming a 0.009% change in cigarette consumption for every percentage change in the input series, suggesting the data are insensitive to detect very small reductions in cigarette consumption. Most Bayes Factors were <1/3 rd , when assuming a 0.1% change in cigarette consumption for every percentage change in the input series, suggesting evidence for the null hypothesis that NRT use and ecigarette use among smokers has not resulted in large reductions in cigarette intake. 
Sensitivity analysis
Current daily use of e-cigarettes among smokers for harm reduction increased from negligible use in the last quarter of 2006 to 11.1% at the end of the study (mean 4.5%, SD 4.91). There was also an increase in e-cigarette use specifically for temporary abstinence (from 0.1% to 8.4%; mean 3.5% SD 3.81) and smoking reduction (from 0.1% to 8.3%; mean 3.3% SD 3.64).
In contrast, there was a decline in the use of NRT for harm reduction from 7.3% to 2.9% (mean 6.5%, SD 2.35) and a decline in NRT use specifically for temporary abstinence (from 7.3% to 1.8%; mean 4.7% SD 2.29) and smoking reduction (from 6.8% to 2.6%; 5.8% SD 2.46). Tables 2, 3 and 4 also show the results of the sensitivity analyses restricted to those smokers using NRT or e-cigarettes daily. The findings were inconclusive as to whether or not an association was present between the daily use of e-cigarettes and NRT for any purpose and cigarette consumption. Bayes Factors suggested the data are insensitive to detect very small reductions in cigarette consumption, but there is evidence for the null hypothesis that NRT use and e-cigarette use among smokers has not resulted in large reductions in cigarette intake.
DISCUSSION
To our knowledge, this is the first empirical study to estimate the population association between the use of e-cigarettes and NRT among current smokers on cigarette consumption per day, using a time-series approach. There was evidence that there was no substantial association between the rise in use of e-cigarettes and decline in NRT use and changes in cigarette consumption per day.
A strength of the study is the use of a large representative sample of the population in England, stratification of results by daily use, and the consideration of both temporary abstinence and smoking reduction. Previous studies have shown that reductions in cigarette intake are dependent on the extent of NRT use and differ as a function of the specific harm reduction behaviour i.e. an attempt to cut down or restraining from smoking during periods of brief abstinence [2 6 ].
The study had a number of limitations. First, caution should be taken when interpreting estimates of the covariates, i.e. impact of some of the tobacco control policies, as interrupted explanatory variables with short time-periods prior to their introduction in ARIMA type models often give inaccurate estimates of the standard errors [28] . Thus, although the increase in age-of-sale has been previously associated with a decline in smoking prevalence [24] , the short lead in period may have masked any true association [27] . Secondly, the STS required participants to recall their average daily cigarette intake which is likely to have been somewhat inaccurate. Thirdly, the findings may not generalise to other countries. England has a strong tobacco control climate and relatively liberal attitude towards harm reduction and e-cigarette use. In countries with weaker tobacco control, or stricter regulation of using products for harm reduction, different effects may be observed. Finally, although we are unaware of any other major population level interventions or other events during the study period, we cannot rule out residual confounding.
The findings are in line with previous studies which show that reductions in cigarette consumption observed in clinical trials of NRT for harm reduction do not appear to generalise beyond the closely controlled trial setting [1 2] . It was hypothesised that ecigarettes may be associated with population mean cigarette intake given that they reduce cravings more effectively than NRT [7 10 11] , have better adherence rates [7 12] , and deliver clinically significant levels of nicotine into the blood [10 11 13] . Of course, it remains plausible that e-cigarettes may still be associated with a very small effect on mean population cigarette consumption [15] , and that a reduction in harm from smoking at a population level could be seen through their promotion of quit attempts [37] or by reducing smoke intake from each cigarette [5] .
In conclusion, the increased prevalence of e-cigarettes use among smokers in England has not been associated with a detectable change in cigarette consumption per day. The decline in the use of NRT has also not been associated with a change in mean cigarette intake. If use of e-cigarettes and licensed nicotine replacement therapy while smoking acts to reduce cigarette consumption, the effect is probably small.
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Strengths and limitations of this study
• Data are observational and so strong conclusions regarding cause and effect cannot be made 
INTRODUCTION
Randomised controlled trials have shown that use of non-tobacco nicotine containing products (e.g. Nicotine Replacement Therapy (NRT)) are efficacious for harm reduction attempts [1] . Harm reduction is defined as any attempt to reduce the harm from smoking without an intention to quit completely, such as, the use of NRT for smoking reduction (i.e. during attempts to cut down) or during periods of temporary abstinence (i.e. during periods of time when one is unable to smoke) [1] . Outside of the clinical setting where little behavioural support is provided, the use of NRT during attempts to cut down appears to increase smoker's propensity to quit, but does not result in significantly large reductions in cigarette consumption [2] [3] [4] . Explanations for this include the lack of behavioural support and possible poor compliance with the medical regimen [5 6 ].
In recent years, there has been an increase in the overall use of nicotine containing products for harm reduction, with a growth in e-cigarettes more than offsetting a decline in the use of NRT [7] [8] [9] . Previous studies suggest that e-cigarettes which contain nicotine reduce cravings more effectively than NRT [7 10 11] , have better adherence rates [7 12 ], and deliver clinically significant levels of nicotine into the blood, at least for some smokers [10 11 13] . Thus, although further studies are needed it is possible that e-cigarettes may be a more effective aid for smoking reduction than licensed nicotine products [14 15 ]. However, it also remains possible that e-cigarettes will not result in clinically significant reductions in cigarette intake at a population level.
The aim of this study was to assess the association between changes in prevalence of e-cigarettes and NRT with changes in mean cigarette consumption per day using a time-series approach. Timeseries analysis allows us to take into account underlying trends, the effect of other tobacco control interventions, autocorrelation (whereby data collected at points closer in time tends to be more similar), and to consider possible lag effects of the independent variable on the dependent variable [16] . Where associations are found, they cannot unequivocally establish a causal association but can be indicative, as has been the case with estimating the effect of price of cigarettes on population consumption [17] , mass media expenditure on use of specialist stop smoking services [18] , and introduction of varenicline to the market on prevalence of use of smoking cessation medication [19] . Where associations are not found, or they go in a direction opposite to that expected, this can also be informative.
1. Current e-cigarette use among smokers for any purpose, current use specifically for smoking reduction, and current use specifically for temporary abstinence 2. Current NRT use among smokers for any purpose, current use specifically for smoking reduction, and current use specifically for temporary abstinence Sensitivity analyses will examine the effect of focusing only on daily e-cigarette and NRT use, given previous associations between extent of non-tobacco nicotine containing product use and the effectiveness of harm reduction attempts [6] .
METHODS
Design
We used ARIMAX modelling of monthly data between 2006 and 2016 primarily from the Smoking Toolkit Study. The STS is a monthly survey of a representative sample of the population in England aged 16+ [20] . This has been collecting data on smoking patterns among smokers and recent exsmokers since November 2006. Questions on the use of e-cigarettes among all smokers were Interviewers then choose which houses within these areas are most likely to fulfil quotas based on the probability of being at home tailored to region and conduct face-to-face computer assisted interviews with one member per household. Participants from the STS appear to be representative of the population in England, having similar socio-demographic composition as other large national surveys, such as the Health Survey for England [20] .
Measures
Explanatory variables
Daily and non-daily smokers were asked the following questions:
1. Which, if any, of the following are you currently using to help you cut down the amount you smoke? 2. Do you regularly use any of the following in situations when you are not allowed to smoke? 3. Can I check, are you using any of the following either to help you stop smoking, to help you cut down or for any other reason at all?
All three questions had the following responses options: nicotine gum, nicotine replacement lozenges\tablets, nicotine replacement inhaler, nicotine replacement nasal spray, nicotine patch, electronic cigarette, nicotine mouth spray, other, none.
Current e-cigarette use was derived by an 'electronic cigarette' response to any of the three questions; e-cigarette use for smoking reduction by a response to the first question; and e-cigarette use for temporary abstinence by a response to the second question.
Current NRT use was derived by a NRT product response ('nicotine gum, nicotine replacement lozenges\tablets, nicotine replacement inhaler, nicotine replacement nasal spray, nicotine patch, or nicotine mouth spray') to any of the three questions; NRT use for smoking reduction by a NRT product response to the first question; and NRT use for temporary abstinence by a NRT product response to the second question.
An 'electronic cigarette' response E-cigarettes: current use Current e-cigarette use was derived by smokers answering electronic cigarettes to any of the Smokers answering electronic cigarettes to any of the three questions were categorised as current e-cigarette users, while smokers answering an NRT product were classed as current NRT users. Responses to the first question were used to derive prevalence of e-cigarette use for smoking reduction and NRT use for smoking reduction, while responses to the second question were used to derive prevalence of e-cigarette for temporary abstinence and NRT use for temporary abstinence. Daily NRT and e-cigarette users were classified as those who reported that they used the product(s) at least once per day in response to the question: How many times per day on average do you use your nicotine replacement product or products? This question was introduced in July-2010. Prior to this time, prevalence of daily NRT use was assumed to be 60% of all users [6] , while e-cigarette prevalence was computed as above using prevalence during a quit attempt or 0.1%.
Outcome variables
Smokers taking part in the STS were also asked how many cigarettes they smoke on average per day. Non-daily smokers were asked how many cigarettes they smoked per week, which was then converted to a daily figure.
Co-variables
In England, tobacco mass media campaigns have been run as part of a national tobacco control programme. Spending was almost completely suspended in 2010 and then re-introduced in 2011 at a much lower level. Previous studies have shown that such cuts were associated with a decreased use of smoking cessation support [18 23 ]. Thus, advertising expenditure will be adjusted for using data obtained from Public Health England. Data on mass media expenditure was available monthly from May 2008, and yearly prior to this period, and so a monthly average was assumed. For a number of months spending was effectively zero and was imputed as 0.1 to allow the analysis to run.
A number of tobacco control policies were adjusted for. These included the move in commissioning of stop smoking services to local authorities in April 2013 [24] , introduction of a smoking ban in July 2007 [25] , licensing of NRT for harm reduction in December 2009 [26] , the publication of NICE guidance on harm reduction in June 2013 [27] , and change in the minimum age of sale of cigarettes October 2007 [28] . Price of cigarettes is correlated 0.99 with time and will thereby be taken into account by use of differencing (i.e. using the differences between consecutive observation rather the observations themselves) to make the series stationary.
Ethical approval:
Ethical approval for the Smoking Toolkit Study was granted by the UCL ethics committee (ID 0498/001).
Analysis
The analysis plan was registered on the Open Science Framework prior to data analysis (https://osf.io/6swk3/). All data were analysed in R version 3.2.4 [29] using Autoregressive Integrated Moving Average with Exogeneous Input (ARIMAX) modelling [16 30 31] . Data were weighted prior to the analyse to match the population in England using a rim (marginal) weighting technique. This involves an iterative sequence of weighting adjustments whereby separate nationally representative target profiles are set (for gender, working status, children in the household, age, social-grade and region). This process is then repeated until all variables match the specified targets (for more details see [20] ). Both unadjusted and fully adjusted models are reported which regressed onto mean cigarette consumption per day 1) use of e-cigarettes among current smokers; 2) use of e-cigarettes for smoking reduction; 3) use of e-cigarettes for temporary abstinence; 4) use of NRT for harm reduction; 5) use of NRT for temporary abstinence and 6) use of NRT for smoking reduction. Sensitivity analyses were conducted which constrained the analysis to only those reporting daily ecigarette and NRT use. We followed a standard ARIMAX modelling approach [16 34] . The series were first log-transformed to stabilise the variance, and if required, first differenced and seasonally differenced. The autocorrelation and partial autocorrelation functions were then examined in order to determine the seasonal and non-seasonal moving average (MA) and autoregressive terms (AR). Bayes factors (BF) were derived for non-significant findings using an online calculator [35] to disentangle whether there is evidence for the null hypothesis of no effect (Bayes Factor <1/3 rd ) or the data are insensitive (Bayes Factor between 1/3 rd and 3). A half-normal distribution was assumed with a percentage change in the outcomes of interest for every percentage increase in the input series of 0.009% based on the effect detectable with 80% power (see sample size). Sensitivity analyses were conducted using a much larger percentage change of 0.1. This was based on a metaanalysis assessing the efficacy of non-tobacco nicotine replacement products for harm reduction, which reported that 21.8% of the experimental group had reduced consumption by more than 50% at final follow-up compared with 16.5% receiving placebo [1] . We therefore assumed that a 5% change in prevalence of NRT and e-cigarettes would be associated with a 0.5% change in overall cigarette consumption.
Sample size
RESULTS
Sample characteristics
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 1 shows that cigarette consumption declined over the study period from 13.6 to 12.3 (mean 12.4, SD 0.92). This figure also shows that current use of e-cigarettes among smokers for harm reduction increased from negligible use in the last quarter of 2006 to 17.1% at the end of the study (mean 7.8%, SD 8.82). Figure 2 shows that there was also a decline in the use of NRT for harm reduction from 12.2% to 6.0% (mean 14.4%, SD 4.36). Supplementary Figures 1 and 2 show the changes in e-cigarette and NRT use for smoking reduction and temporary abstinence, respectively. Tables 1, 2 and 3 show the results of the ARIMAX models assessing the association between cigarette consumption per day with 1) e-cigarette use among current smokers and NRT use for harm reduction; 2) e-cigarette and NRT use for smoking reduction and 3) e-cigarette and NRT use for temporary abstinence. The findings were inconclusive as to whether or not an association was present between use of e-cigarettes and NRT for any purpose and cigarette consumption.
Main analysis
Bayes Factors were between 1/3 rd and 3 when assuming a 0.009% change in cigarette consumption for every percentage change in the input series, suggesting the data are insensitive to detect very small reductions in cigarette consumption. Most Bayes Factors were <1/3 rd , when assuming a 0.1% change in cigarette consumption for every percentage change in the input series, suggesting evidence for the null hypothesis that NRT use and e-cigarette use among smokers has not resulted in large reductions in cigarette intake.
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Sensitivity analysis
In contrast, there was a decline in the use of NRT for harm reduction from 7.3% to 2.9% (mean 6.5%, SD 2.35) and a decline in NRT use specifically for temporary abstinence (from 7.3% to 1.8%; mean 4.7% SD 2.29) and smoking reduction (from 6.8% to 2.6%; 5.8% SD 2.46). Tables 1, 2 and 3 also show the results of the sensitivity analyses restricted to those smokers using NRT or e-cigarettes daily. The findings were inconclusive as to whether or not an association was present between the daily use of e-cigarettes and NRT for any purpose and cigarette consumption. Bayes Factors suggested the data are insensitive to detect very small reductions in cigarette consumption, but there is evidence for the null hypothesis that NRT use and e-cigarette use among smokers has not resulted in large reductions in cigarette intake.
DISCUSSION
Strengths and limitations
The study had a number of limitations. First, caution should be taken when interpreting estimates of the covariates, i.e. impact of some of the tobacco control policies, as interrupted explanatory variables with short time-periods prior to their introduction in ARIMA type models often give inaccurate estimates of the standard errors [28] . Thus, although the increase in age-of-sale has been previously associated with a decline in smoking prevalence [24] , the short lead in period may have masked any true association [27] . Secondly, the STS required participants to recall their average daily cigarette intake which is likely to have been somewhat inaccurate. Thirdly, the findings may not generalise to other countries. England has a strong tobacco control climate and relatively liberal attitude towards harm reduction and e-cigarette use. In countries with weaker tobacco control, or stricter regulation of using products for harm reduction, different effects may be observed. Fourthly, although we are unaware of any other major population level interventions or other events during the study period, we cannot rule out residual confounding. Fifthly, participants were not asked questions regarding potentially important features of the e-cigarette (e.g., nicotine content, flavouring, device type) or frequency and duration of use. It is likely that these factors may play a role in their effectiveness and should be considered in future studies [15 39 ]. Finally, as data were not collected on current e-cigarette use prior to April 2011, prevalence was estimated from use during a quit attempt or from previous studies [21 22 ]. This was necessary to ensure that the time series was long enough for an ARIMAX analysis and is an appropriate approach when data are 
Implications of findings
The findings are in line with previous studies which show that reductions in cigarette consumption observed in clinical trials of NRT for harm reduction do not appear to generalise beyond the closely controlled trial setting [1 2] . It was hypothesised that e-cigarettes may be associated with population mean cigarette intake given that they reduce cravings more effectively than NRT [7 10 11] , have better adherence rates [7 12] , and deliver clinically significant levels of nicotine into the blood [10 11 13] [11].
The finding that e-cigarette use was not associated with reductions in consumption at a population level is consistent with previous real-world studies at the individual level. These have found little change in consumption among ever e-cigarette users [41] and that only a minority of daily users manage to reduce by a substantial amount which is not likely to be detected at a population level [42] . The findings of a recent pragmatic controlled trial, whereby 60% of participants using ecigarettes had managed to reduce by over 50% by 6 months follow-up, suggests that the lack of effectiveness at a population level may not be the consequence of poor behavioural support [11] . .
Of course, it remains plausible that e-cigarettes may still be associated with a small effect on mean population cigarette consumption [15] , and that a reduction in harm from smoking at a population level could be seen through their promotion of quit attempts [37] or by reducing smoke intake from each cigarette [5] .
Conclusion
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Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
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